When innovation merges with integrated end-to-end CDMOs, biopharmaceutical clients embed speed, consistency, and quality into manufacturing at scale. Digital twins amplify this impact, de-risking technology transfers, accelerating scale-up, and enabling right-first-time launches.
Heejeong Kim, our Vice President in Drug Substance Manufacturing, provides her thought leadership on how bioprocess digital twins are strategic engines that set future pathways for the biopharmaceutical industry.
When innovation merges with integrated end-to-end CDMOs, biopharmaceutical clients embed speed, consistency, and quality into manufacturing at scale. Digital twins amplify this impact, de-risking technology transfers, accelerating scale-up, and enabling right-first-time launches.
Heejeong Kim, our Vice President in Drug Substance Manufacturing, provides her thought leadership on how bioprocess digital twins are strategic engines that set future pathways for the biopharmaceutical industry.
Share article
Related Content